Humigent Raises Series A for Life-Sciences AI
Humigent raised Series A funding for an AI-native life-sciences platform built around specialised agents and scientific context.
Life-sciences AI is moving beyond generic chatbots into specialised workflow platforms.
What happened
Humigent closed a Series A with participation from Z21 Ventures and First Rays Ventures.
The company is building an AI-native platform for life sciences, using a proprietary 30B-parameter life-sciences language model, specialised agents and a context-intelligence layer.
Its pitch is that scientific teams need AI systems that understand research data, internal knowledge and regulated workflows, rather than general-purpose tools that lack domain context.
Why it matters
Life sciences is one of the most promising but difficult markets for AI. The data is complex, the workflows are specialised, and mistakes can have serious scientific, regulatory or commercial consequences.
That makes context especially important. A useful AI system needs to understand not only the words in a document, but also experimental history, institutional knowledge, scientific relationships and workflow constraints.
Humigent is aiming at that deeper layer.
The bigger picture
Vertical AI is becoming a major enterprise theme. Instead of trying to make one general model serve every industry, startups are building specialised systems for law, finance, healthcare, engineering and life sciences.
Humigent’s funding fits that trend: the future of enterprise AI may depend less on who has the biggest model, and more on who can connect models to the right domain knowledge and workflow context.